KIT and ischemic cardiomyopathy: The SCIPIO clinical trial, the first in man to investigate c-kit + CSCs, reported that 16 patients with ischemic cardiomyopathy received intracoronary infusions of 0.5-1 × 106 c-kit +, autologous CSCs and compared to controls these patients benefited from an 8 and 12 unit increase in left ventricular ejection fraction, 4 and 12 months after infusion, respectively (Bolli et al., 2011).